News and Updates

A study shows the Selinexor-Ruxolitinib combination meets primary endpoints for myelofibrosis, offering a new hope for patients failing JAK inhibitors.

New trial data confirms pirtobrutinib slashes CLL progression risk by 45%. Explore the clinical impact of this breakthrough BTK inhibitor for oncology.

Explore the projected growth of the decentralized clinical trials market through 2034 and how digital health tech is transforming global drug development.

Discover how the synergy between AI technology and clinical expertise is revolutionizing patient matching for cancer trials and accelerating research.

The FDA has cleared the first OTC continuous glucose monitor for children, improving access to real-time diabetes tracking and pediatric glycemic management.

Discover the future of medical research as the decentralized clinical trials market scales globally. Explore key trends, AI integration, and 2034 forecasts.

The FDA has authorized the first OTC continuous glucose monitor for children. Discover how this wearable tech is changing pediatric diabetes management.

Paradigm completes enrollment for a pivotal Phase 3 osteoarthritis trial. Discover what this milestone means for the future of knee pain treatments.

Mabwell has received FDA approval for the clinical trial of its novel injection, 6MW5311. Learn about this major development in drug innovation.

The FDA has approved the clinical trial application for Mabwell’s 6MW5311 injection. Learn more about this new development in targeted biologic therapy.